Viking launches Phase 3 oral obesity trials
Viking Therapeutics (NASDAQ:VKTX) announced the start of its SUNRISE Phase 3 clinical program for oral VK2735, an investigational therapy being developed for obesity management.
Viking Therapeutics (NASDAQ:VKTX) announced the start of its SUNRISE Phase 3 clinical program for oral VK2735, an investigational therapy being developed for obesity management.
Alpha Compute (NASDAQ:ALP) announced that it entered into a binding GPU compute services agreement on October 9, 2026, for its first contracted U.S. GPU cluster.
Parabilis Medicines (NASDAQ:PBLS) announced the initiation of a new dose-ranging cohort for zolucatetide in adults with familial adenomatous polyposis, a hereditary condition associated with the development of precancerous polyps.
Guillaume Princen, Anthropic Head of International Startups & Digital Native, joins Bloomberg's Tom Mackenzie on "The Opening Trade" to discuss how artificial intelligence will impact businesses, customer spending on frontier models, and AI safety risks. They speak from the International AI Summit in Dublin, Ireland.
Christopher Hodge, chief US economist at Natixis, expects core CPI to come in slightly softer than forecast and sees inflation continuing to ease. He discusses the impact of higher energy prices, potential labor market weakness and housing pressures, while forecasting one final Fed rate hike in December before the tightening cycle ends. He spoke on Bloomberg Brief.
Takeda Pharmaceutical (NYSE:TAK) presented new data from the pivotal Phase 2/3 IgGNITE clinical trial (TAK-881-3001) evaluating TAK-881 Immune Globulin Subcutaneous (Human), 20% Solution combined with recombinant human hyaluronidase.
Morgan Stanley saw third quarter profit rise as the firm's equity traders topped analysts' estimates and a record amount of money was brought in by the bank's wealth-management operation. Kristine Aquino reports on Bloomberg Television.
Entrada Therapeutics (NASDAQ:TRDA) announced that an independent monitoring committee has recommended initiating Cohort 3 of its Phase 1/2 ELEVATE-44-201 clinical study.
Fusion Fuel (NASDAQ:HTOO) reported first-half 2026 financial results and provided its outlook for the remainder of the year.
Bank of America's stock and fixed-income traders missed estimates in the third quarter, with bond-trading revenue falling 17% and equity trading down 10%. Chris Marinac, director of research at Brean Capital, examines the results on "Bloomberg Surveillance."
OpenAI Chief Financial Officer Sarah Friar discusses artificial intelligence security concerns, telling Bloomberg's Tom Mackenzie that the firm is "doubling down" on safety and alignment, and is holding back its next generation model while it carries out checks.
Morgan Stanley (NYSE:MS) reported third-quarter 2026 financial results, beating analyst expectations on both revenue and earnings.
Got a second for a cookie? 🍪Essential cookies keep Grafa running smoothly. A few optional ones help us see what's working so we can make it better. You're in control — change your mind any time. Cookie policy · Privacy policy